Lymphoma, Follicular
Information
- Disease name
- Lymphoma, Follicular
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02996773 | Active, not recruiting | Phase 1 | Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine | November 29, 2016 | August 25, 2025 |
| NCT05784415 | Active, not recruiting | Observational Study of People Living With HIV Treated With CD19-directed CAR T Cell | February 16, 2021 | August 31, 2025 | |
| NCT02390869 | Active, not recruiting | Phase 3 | Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-chemoterapy for Relapsed/Refractory FL Patients | May 2014 | December 2027 |
| NCT00315731 | Completed | Phase 1 | A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma | March 31, 2003 | June 30, 2013 |
| NCT00915096 | Completed | Positron Emission Tomography (PET)-Scan in the Evaluation of High Tumor Burden Follicular Lymphoma | September 18, 2007 | February 8, 2013 | |
| NCT00081809 | Completed | Phase 2 | A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma | March 2000 | June 2005 |
| NCT00193492 | Completed | Phase 2 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | September 2005 | March 2013 |
| NCT00394836 | Completed | Phase 2 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | May 2007 | September 2013 |
| NCT00427856 | Completed | Phase 2 | Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL) | March 2007 | July 2009 |
| NCT00475644 | Completed | Phase 2 | A Study of Enzastaurin in Participants With Follicular Lymphoma | May 2007 | December 2014 |
| NCT00494780 | Completed | Phase 2 | Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients | June 2007 | September 2010 |
| NCT00546793 | Completed | Phase 1/Phase 2 | Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL | January 2008 | March 2013 |
| NCT00849147 | Completed | Phase 2 | Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) | October 2008 | November 2013 |
| NCT00864227 | Completed | Phase 2 | Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) | December 2008 | November 2013 |
| NCT00930514 | Completed | Phase 1 | A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma | September 2009 | July 2013 |
| NCT01022255 | Completed | Phase 1 | Autologous Vaccine for Follicular Lymphoma | January 2010 | October 2013 |
| NCT01164696 | Completed | A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin | August 2007 | May 2009 | |
| NCT01208896 | Completed | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma | February 3, 2011 | September 28, 2017 |
| NCT01234766 | Completed | Phase 2 | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma | October 2010 | April 1, 2021 |
| NCT01250223 | Completed | Study of Prognosis of Follicular Lymphoma Through a Prospective Collection of Data (F2-study) | February 2003 | December 2016 | |
| NCT01307267 | Completed | Phase 1 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | June 21, 2011 | February 20, 2019 |
| NCT01584141 | Completed | Study of Lymphoma in Asia | July 5, 2011 | July 10, 2018 | |
| NCT01786135 | Completed | Phase 1 | A Safety Study of SGN-CD19A for B-Cell Lymphoma | February 2013 | February 16, 2017 |
| NCT01950273 | Completed | Phase 1 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | September 27, 2013 | December 22, 2015 |
| NCT02162771 | Completed | Phase 3 | To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan | July 14, 2014 | December 29, 2018 |
| NCT02208037 | Completed | Phase 2 | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) | August 2014 | October 2017 |
| NCT02257242 | Completed | Phase 1 | Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma | May 10, 2017 | November 18, 2020 |
| NCT02278796 | Completed | Phase 2 | A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial) | April 2015 | November 2020 |
| NCT02343536 | Completed | Phase 1 | A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma | April 29, 2015 | January 29, 2020 |
| NCT02472756 | Completed | A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma | September 19, 2008 | May 30, 2014 | |
| NCT02569996 | Completed | Phase 3 | A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma | July 2005 | August 2013 |
| NCT02631577 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | December 31, 2015 | October 7, 2020 |
| NCT02669017 | Completed | Phase 1 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | March 2016 | February 21, 2019 |
| NCT02809053 | Completed | Phase 3 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma | January 18, 2017 | January 10, 2020 |
| NCT03057418 | Completed | Phase 1 | Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim | June 2013 | December 2016 |
| NCT03087929 | Completed | Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon | September 20, 2013 | March 15, 2017 | |
| NCT03310619 | Completed | Phase 1/Phase 2 | A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | December 20, 2017 | February 15, 2023 |
| NCT03357627 | Completed | Phase 1 | A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma | February 16, 2018 | August 3, 2021 |
| NCT03682796 | Completed | Phase 1 | Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma | October 15, 2018 | November 17, 2021 |
| NCT04036448 | Completed | A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea | August 18, 2019 | August 15, 2023 | |
| NCT04911478 | Enrolling by invitation | Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells | February 14, 2022 | August 2039 | |
| NCT05106192 | Not yet recruiting | N/A | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | June 1, 2024 | February 1, 2025 |
| NCT06213636 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). | November 10, 2024 | December 10, 2025 |
| NCT06425302 | Not yet recruiting | Phase 2 | A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma | August 3, 2024 | November 27, 2028 |
| NCT06290622 | Not yet recruiting | Phase 1 | PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL | June 30, 2024 | January 31, 2028 |
| NCT05616325 | Not yet recruiting | Long-term Ovarian Fertility in Patients Treated for Lymphoma. | March 2023 | March 2029 | |
| NCT04735471 | Recruiting | Phase 1 | A Phase 1 Study of ADI-001 in B Cell Malignancies | March 4, 2021 | December 31, 2027 |
| NCT05410418 | Recruiting | Phase 2 | Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma | October 24, 2022 | October 31, 2031 |
| NCT05849857 | Recruiting | Phase 2 | Mosunetuzumab for Early Relapse of Follicular Lymphoma in the Nordic Countries | September 11, 2023 | August 2028 |
| NCT03934567 | Recruiting | Phase 2 | A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma | April 22, 2020 | September 30, 2024 |
| NCT06045910 | Recruiting | Phase 1/Phase 2 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | January 19, 2024 | December 2027 |
| NCT05228158 | Recruiting | A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan | August 16, 2021 | March 31, 2028 | |
| NCT04982471 | Recruiting | Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study | November 5, 2021 | July 30, 2029 | |
| NCT02376699 | Terminated | Phase 1 | Safety Study of SEA-CD40 in Cancer Patients | February 28, 2015 | April 14, 2023 |
| NCT00384111 | Terminated | Phase 3 | Phase 3 Study of Zevalin Following R-CVP in Previously Untreated Patients With Follicular Non Hodgkin's Lymphoma (NHL) | October 2006 | November 2008 |
| NCT02413489 | Terminated | Phase 2 | An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma | September 2, 2015 | June 1, 2017 |
| NCT02440685 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | May 2015 | July 2018 |
| NCT02454270 | Terminated | Phase 1 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | June 15, 2015 | July 26, 2018 |
| NCT00510887 | Terminated | Phase 2 | Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma | January 2007 | September 2013 |
| NCT00562965 | Terminated | Phase 3 | Study Comparing Inotuzumab Ozogamicin In Combination With Rituximab Versus Defined Investigator's Choice In Follicular Non-Hodgkin's Lymphoma (NHL) | November 2007 | April 2011 |
| NCT00060671 | Terminated | Phase 3 | Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma | January 2005 | January 2006 |
| NCT01077518 | Terminated | Phase 3 | Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy | August 26, 2010 | December 26, 2018 |
| NCT00308087 | Terminated | Phase 2 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma | May 2006 | June 2009 |
| NCT01609036 | Terminated | An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma | October 2012 | November 2012 | |
| NCT01902862 | Terminated | Phase 2 | An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma | February 2006 | August 2007 |
| NCT02086591 | Terminated | Phase 2 | A Phase II Study of Doxycycline in Relapsed NHL | March 2014 | November 2015 |
| NCT04370405 | Unknown status | Phase 2 | A Study of YY-20394 in Participants With Relapsed/Refractory Follicular Non-Hodgkin's Lymphoma | April 29, 2019 | February 22, 2021 |
| NCT00317096 | Unknown status | Phase 3 | FCM Versus R-FCM Followed by R-Maintenance or Observation Only | November 1998 | June 2021 |
| NCT03921879 | Unknown status | Phase 1 | Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma | July 29, 2019 | June 2021 |
| NCT00319332 | Withdrawn | Phase 3 | A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen | September 2005 | February 2021 |
| NCT02743546 | Withdrawn | Phase 1 | Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma | July 20, 2016 | March 31, 2020 |
| NCT01263418 | Withdrawn | Phase 2 | Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas | June 2011 | January 2018 |
| NCT00092274 | Withdrawn | Phase 1/Phase 2 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | September 2004 | January 2005 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008224